Pindolol
Overview
Pindolol is oral, nonselective, ß-receptor antagonist with intrinsic sympathomimetic activity (ISA) (i.e., partial agonist activity). Pindolol is the ß-blocker with the highest degree of ISA and nonselective antagonist qualities. The effect of ISA, as with ß-blockade in general, can be selective or nonselective in nature. The partial agonist potential of Pindolol is greater for ß 2- than ß1-receptors, a characteristic that renders the drug a "vasodilatory" ß-blocker. It was approved by the FDA in September 1982 for the treatment of hypertension. Like other ß-adrenergic antagonists, it competes with adrenergic neurotransmitters (e.g., catecholamines) for binding at sympathetic receptor sites, similar to propranolol.
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Pindolol's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 10 to 40 mg | 25 (25) | 24 hourly | PO | |
Paedriatic Dosage (20kg)
|
| | | | Not recommended for this age group |
Neonatal Dosage (3kg)
|
| | | | Not recommended in this age group |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Pindolol
Back to top
Previous Drug Generic - Next Drug Generic